FDA grants Orphan Drug Status to Allon’s davunetide for brain disease
Gordon McCauley, President and CEO of Allon, said Orphan Drug Designation brings additional commercial benefits to the Company’s program to develop davunetide to become the first approved treatment for a disease often mis-diagnosed as Parkinson’s or Alzheimer’s disease.
“PSP is devastating for thousands of middle-age patients and their families,” said McCauley. “Meeting the desperate need for a treatment is a significant business opportunity for Allon made more attractive by the FDA’s Orphan Drug Designation for davunetide.”
McCauley said Allon has demonstrated a strong scientific and clinical rationale for the potential efficacy of davunetide in PSP. “The pathology of PSP and Alzheimer’s is similar in that both diseases involve impairment of the brain protein tau — and we have shown that davunetide is the most advanced tau therapy in the world.”
McCauley said davunetide’s potential as a treatment for PSP was confirmed in both animal studies and Phase II human clinical trials with patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s.
“Our research has shown that davunetide reduced tau impairment and preserved memory in mice bred to replicate Alzheimer’s or PSP tau pathology. In addition, our Phase II clinical trials have shown that davunetide can also improve memory function in aMCI patients.”
Allon’s clinical program in this area is expected to begin shortly with a Pilot trial treating a small number of patients with tau impairments, including PSP. This trial will help validate the trial design and prepare for a larger Phase II clinical trial that the Company intends to initiate in 2010. Trial investigators are among the leading experts in the field, including Drs. Bruce Miller and Adam Boxer of the Memory and Aging Center of the University of California, San Francisco.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.